BMC pulmonary medicine
-
BMC pulmonary medicine · Mar 2010
Randomized Controlled Trial Multicenter StudyEfficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.
Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting beta2-agonist in development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-severe COPD. ⋯ Indacaterol 150 microg o.d. provided clinically significant and sustained bronchodilation, reduced rescue medication use, and had a safety and tolerability profile similar to placebo.